Download PDF
Nervenheilkunde 2012; 31(10): 699-707
DOI: 10.1055/s-0038-1628182
Update Neurologie
Schattauer GmbH

Pharmakologische Behandlungsmöglichkeiten bei therapieresistenter Depression

Pharmacological treatment options in therapy resistant depression
K. G. Kahl
1   Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

Eingegangen am: 23 April 2012

angenommen am: 29 May 2012

Publication Date:
23 January 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die therapieresistente Depression (TRD) ist ein häufiges Problem in der klinischen Versorgung. Im Gegensatz zu depressiven Episoden hat die TRD eine schlechtere klinische, funk-tionelle und soziale Prognose. Es besteht eine Reihe von Optionen zur Therapie der TRD, die Evidenzlage ist – nicht zuletzt aufgrund der uneinheitlichen Operationalisierung von TRD – schmal. Neue Therapiestrategien, die auf eine Veränderung von Neurotransmittersystemen außerhalb der klassischen Monoaminhypothese zielen, werden mit vielversprechenden Ergebnissen untersucht. Augmentations- und Kombinationsstrategien mit Lithium, atypischen Neuroleptika und neueren Antidepressiva sind eine interessante und valide Option.

Summary

Treatment-resistant depression (TRD) is frequently been observed in patients with severe mental disorders. The clinical course, functional and social prognosis is worse in TRD compared to patients with depressive episodes. Several options exist for the treatment of TRD, including pharmacologic treatment beyond the “classical” monoamine hypothesis of depression. Augmentation with lithium or atypical neuroleptics, and combination treatments are promising strategies. Cognitive-behavioral psychotherapy and “third wave” psychotherapies should always be considered as part of the treatment plan.

Schlüsselwörter

Therapieresistente Depression - Augmentation - Switching - Kombination - Psychotherapie

Keywords

Treatment-resistant depression - augmentation - switching - combination - psychotherapy
 

  • Literatur

  • 1 Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-59.
    CrossrefPubMedSearch in Google Scholar
  • 2 Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007; 41: 189-206.
    CrossrefPubMedSearch in Google Scholar
  • 3 Fava M. et al. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200.
    CrossrefPubMedSearch in Google Scholar
  • 4 Gunther OH. et al. [The burden of depressive disorders in Germany – results from the European Study of the Epidemiology of Mental Disorders (ESEMeD)]. Psychiatr Prax 2007; 34: 292-301.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Fostick L. et al. The economic impact of depression: resistance or severity?. Eur Neuropsychopharmacol 2010; 20: 671-5.
    CrossrefPubMedSearch in Google Scholar
  • 6 Murphy JA. et al. Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord 2012; 139: 172-80.
    CrossrefPubMedSearch in Google Scholar
  • 7 Carney AT. et al. Is there a high-risk subtype of depression in patients with coronary heart disease?. Curr Psychiatry Rep 2012; 14: 1-7.
    CrossrefPubMedSearch in Google Scholar
  • 8 Kahl G. et al. Prevalence of the metabolic syndrome in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 2012; 262: 313-20.
    CrossrefPubMedSearch in Google Scholar
  • 9 Kleon DN. et al. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry 2006; 163: 872-80.
    CrossrefPubMedSearch in Google Scholar
  • 10 Satanyarar J. et al. Prevalence and correlates of chronic depression in the canadian community health survey: mental health and well-being. Can J Psychiatry 2009; 54: 389-98.
    CrossrefPubMedSearch in Google Scholar
  • 11 Berlim T. et al. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52: 46-54.
    CrossrefPubMedSearch in Google Scholar
  • 12 Thase ME. et al. When at first you don‘t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58 Suppl 13: 23-9.
    PubMedSearch in Google Scholar
  • 13 Sourey J. et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007; 68: 1062-70.
    CrossrefPubMedSearch in Google Scholar
  • 14 Rush AJ. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17.
    CrossrefPubMedSearch in Google Scholar
  • 15 Trevidi J. et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004; 61: 669-80.
    CrossrefPubMedSearch in Google Scholar
  • 16 Ricken R. et al. Algorithm-guided treatment of depression reduces treatment costs--results from the randomized controlled German Algorithm Project (GAPII). J Affect Disord 2011; 134: 249-56.
    CrossrefPubMedSearch in Google Scholar
  • 17 Bauer M. et al. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 2009; 29: 327-33.
    CrossrefPubMedSearch in Google Scholar
  • 18 Adli M. et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400.
    CrossrefPubMedSearch in Google Scholar
  • 19 Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol 2002; 17: 335-9.
    CrossrefPubMedSearch in Google Scholar
  • 20 Pridmores S. et al. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiatry 2004; 38: 219-25.
    CrossrefPubMedSearch in Google Scholar
  • 21 Vieta E. et al. Therapeutic options in treatment-resistant depression. Ann Med 2011; 43: 512-30.
    CrossrefPubMedSearch in Google Scholar
  • 22 Katz AJ. et al. Distressing adverse events after antidepressant switch in the sequenced treatment alternatives to relieve depression (STAR*D) trial: Influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy 2012 E-Pub ahead of print.
    PubMedSearch in Google Scholar
  • 23 Thase ME. et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233-9.
    CrossrefPubMedSearch in Google Scholar
  • 24 Papakostas GI. et al. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008; 63: 699-704.
    CrossrefPubMedSearch in Google Scholar
  • 25 Bschor T. et al. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121: 174-9.
    CrossrefPubMedSearch in Google Scholar
  • 26 Fleurence R. et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009; 42: 57-90.
    PubMedSearch in Google Scholar
  • 27 Berman ME. et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
    CrossrefPubMedSearch in Google Scholar
  • 28 McKleroy ME. et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71: 163-74.
    CrossrefPubMedSearch in Google Scholar
  • 29 Arbaizer J. et al. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009; 31: 478-83.
    CrossrefPubMedSearch in Google Scholar
  • 30 Bobo WV. et al. Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial. Hum Psycho-pharmacol 2010; 25: 30-6.
    CrossrefPubMedSearch in Google Scholar
  • 31 Lane HY. et al. Risperidone monotherapy for mania and depression. Am J Psychiatry 1999; 156: 1115.
    PubMedSearch in Google Scholar
  • 32 Barbee JG. Treatment-resistant depression: adding low dose risperidone improves symptoms. Evid Based Ment Health 2008; 11: 77.
    CrossrefPubMedSearch in Google Scholar
  • 33 Thase ME. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry 2011; 56: 317-23.
    CrossrefPubMedSearch in Google Scholar
  • 34 Stein G. et al. Lithium augmentation therapy in tri-cyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634-40.
    CrossrefPubMedSearch in Google Scholar
  • 35 Baumann P. et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-14.
    CrossrefPubMedSearch in Google Scholar
  • 36 Nierenberg AA. et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003; 23: 92-5.
    CrossrefPubMedSearch in Google Scholar
  • 37 Crossley NA. et al. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-40.
    CrossrefPubMedSearch in Google Scholar
  • 38 Bschor T. et al. [Twenty-five years of lithium augmentation]. Nervenarzt 2007; 78: 1237-47.
    CrossrefPubMedSearch in Google Scholar
  • 39 Nemeroff CB. Augmentation strategies in patients with refractory depression. Depress Anxiety 1996; 4: 169-81.
    CrossrefPubMedSearch in Google Scholar
  • 40 Guttierez J. et al. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr 2005; 10: 800-5.
    CrossrefPubMedSearch in Google Scholar
  • 41 Barbee JN. et al. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002; 63: 737-41.
    CrossrefPubMedSearch in Google Scholar
  • 42 Barbosa L. et al. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003; 64: 403-7.
    CrossrefPubMedSearch in Google Scholar
  • 43 Santos C. et al. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008; 10: 187-90.
    CrossrefPubMedSearch in Google Scholar
  • 44 Appelberg BG. et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448-52.
    CrossrefPubMedSearch in Google Scholar
  • 45 Bech P. et al. Outcomes on the pharmacopsycho-metric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012; 125: 342-8.
    CrossrefPubMedSearch in Google Scholar
  • 46 Carvaholo AF. et al. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007; 32: 415-28.
    CrossrefPubMedSearch in Google Scholar
  • 47 Patkaar J. et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26: 653-6.
    CrossrefPubMedSearch in Google Scholar
  • 48 Ravinden AV. et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008; 69: 87-94.
    CrossrefPubMedSearch in Google Scholar
  • 49 Fava M. et al. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66: 85-93.
    CrossrefPubMedSearch in Google Scholar
  • 50 Thase M. et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006; 11: 93-102.
    CrossrefPubMedSearch in Google Scholar
  • 51 Fang J. et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011; 31: 638-42.
    PubMedSearch in Google Scholar
  • 52 Kahl KG. et al. [The third wave of cognitive-behavioural psychotherapies: concepts and efficacy]. Fortschr Neurol Psychiatr 2011; 79: 330-9.
    Thieme ConnectPubMedSearch in Google Scholar
  • 53 Kahl KG. et al. Combination of agomelatine and bupropione for treatment-resistant depression: a case series. Poster No. 76, 20th European Congress of Psychiatry; 2012. Prag:
    Search in Google Scholar
  • 54 Kahl KG. Individualisierte Therapie der Depression – Möglichkeiten und Herausforderungen. Nervenheilkunde 2012; 31: 295-304.
    Thieme ConnectSearch in Google Scholar
  • 55 Winter L. et al. Individualisierte Psychotherapie bei Major Depression – Neue Verfahren bieten neue Möglichkeiten. Nervenheilkunde 2012; 31: 316-20.
    Thieme ConnectSearch in Google Scholar
  • 56 Sühs KW. et al. Therapie der Depression bei kardiometabolischen Erkrankungen. Nervenheilkunde 2012; 31: 311-5.
    Thieme ConnectSearch in Google Scholar
  • 57 Hillemacher H. et al. Depression und Akoholabhängigkeit – Eine therapeutische Herausforderung. Nervenheilkunde 2012; 31: 305-10.
    Thieme ConnectSearch in Google Scholar
  • 58 Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002; 63: 685-93.
    CrossrefPubMedSearch in Google Scholar
  • 59 Nelson JC, Price LH. Lithium or desipramine augmentation of fluoxetine treatment. Am J Psychiatry 1995; 152: 1538-9.
    CrossrefPubMedSearch in Google Scholar
  • 60 Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004; 65: 337-40.
    CrossrefPubMedSearch in Google Scholar
  • 61 Benkert O, Hippius H. (Hrsg.). Kompendium der psychiatrischen Pharmakotherapie. Berlin: Springer-Verlag; 2011
    Search in Google Scholar
  • 62 Berman RM. et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-53.
    CrossrefPubMedSearch in Google Scholar
  • 63 Berman RM. et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
    CrossrefPubMedSearch in Google Scholar
  • 64 Marcus RN. et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156-65.
    CrossrefPubMedSearch in Google Scholar
  • 65 Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-91.
    CrossrefPubMedSearch in Google Scholar